Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Cytokinetics Q2 2024 GAAP EPS $(1.31) Misses $(1.02) Estimate

Author: Benzinga Newsdesk | August 08, 2024 04:42pm

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(1.02) by 28.43 percent.

Posted In: CYTK